Unknown

Dataset Information

0

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.


ABSTRACT: Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study was a double-blind, randomized, controlled trial comparing vilazodone 20 and 40 mg/day with placebo; citalopram 40 mg/day was an active control (NCT01473381; http://www.clinicaltrials.gov). Post-hoc analyses evaluated change from baseline to week 10 on the Changes in Sexual Functioning Questionnaire (CSFQ); no inferential statistics were performed. CSFQ scores increased for women [1.2 (citalopram) to 3.0 (vilazodone 40 mg)] and men [1.2 (vilazodone 40 mg) to 3.5 (placebo)] in all treatment groups. Greater changes in CSFQ scores were seen in responders [women: 2.33 (citalopram) to 5.06 (vilazodone 40 mg); men: 2.26 (vilazodone 40 mg) to 4.35 (placebo)] versus nonresponders. CSFQ change from baseline was small for patients with normal baseline sexual function; in patients with baseline sexual dysfunction, CSFQ scores improved across groups [women: 2.35 (citalopram) to 4.52 (vilazodone 40 mg); men 2.83 (vilazodone 40 mg) to 6.43 (placebo)]. Across treatment groups, baseline sexual function improved in women and men, MDD responders, and patients with baseline sexual dysfunction.

SUBMITTER: Clayton AH 

PROVIDER: S-EPMC4457500 | BioStudies | 2015-01-01

SECONDARY ACCESSION(S): NCT00285376

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4314105 | BioStudies
2016-01-01 | S-EPMC4922821 | BioStudies
1000-01-01 | S-EPMC5131696 | BioStudies
2016-01-01 | S-EPMC5135073 | BioStudies
2018-01-01 | S-EPMC6028869 | BioStudies
2014-01-01 | S-EPMC4048141 | BioStudies
2020-01-01 | S-EPMC7409584 | BioStudies
2015-01-01 | S-EPMC4676920 | BioStudies
2017-01-01 | S-EPMC5540350 | BioStudies
2018-01-01 | S-EPMC5991171 | BioStudies